A review of disease burden and clinical management for generalized pustular psoriasis in China

References

• Bachelez H. pustular psoriasis: the dawn of a new era. Acta Derm Venereol. 2020;100:adv00034.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907–919.
   PubMed Web of Science ®Google Scholar
• Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16:669–673.
   PubMed Web of Science ®Google Scholar
• Feng Q, Guo J, Zhang Q, et al. Evaluation of prevalence and disease burden of generalized pustular psoriasis in China: based on data (2012-2016) from the national health insurance database. unpublished. 2021
   Google Scholar
• Yu S, Luo Z. clinical analysis of 120 patients with generalized pustular psoriasis. Zhongguo Mafeng Pifubing Zazhi. 2019;5:260–5,75.
   Google Scholar
• Li Y, Gan X, Xiao R, et al. Clinical analysis of 32 adult patients with acute generalized pustular psoriasis. Linchuang Pifuke Zazhi. 2004;6:351–352.
   Google Scholar
• Niu R, Lu G, Zhang HE. Clinical analysis of 92 patients with generalized pustular psoriasis. Zhongguo Pifu-Xingbingxue Zazhi. 2012;2:129–131.
   Google Scholar
• Mössner R, Wilsmann-Theis D, Oji V, et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018;178:740–748.
   PubMed Web of Science ®Google Scholar
• Kharawala S, Golembesky AK, Bohn RL, et al. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16:239–252.
   PubMed Web of Science ®Google Scholar
• Luo Y. Clinical analysis of 130 patients with generalized pustular psoriasis [Master thesis]. China Medical University; 2017.
   Google Scholar
• Choon SE, Lai NM, Mohammad NA, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53:676–684.
   PubMed Web of Science ®Google Scholar
• Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109–120.
   PubMed Web of Science ®Google Scholar
• Benjegerdes KE, Hyde K, Kivelevitch D, et al. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131–144.
   PubMed Web of Science ®Google Scholar
• Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143:1021–1026.
   PubMed Web of Science ®Google Scholar
• Li L. Association of gene IL36RN, CARD14 and AP1S with generalized pustular psoriasis in Chinese Han population. China: Jinan University; 2018.
   Google Scholar
• Li X, Chen M, Fu X, et al. Mutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with/without psoriasis vulgaris. J Dermatol Sci. 2014;76:132–138.
   PubMed Web of Science ®Google Scholar
• Li M, Han J, Lu Z, et al. Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris. J Invest Dermatol. 2013;133:2637–2639.
   PubMed Web of Science ®Google Scholar
• Setta-Kaffetzi N, Navarini AA, Patel VM, et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013;133:1366–1369.
   PubMed Web of Science ®Google Scholar
• Berki DM, Liu L, Choon SE, et al. Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris. J Invest Dermatol. 2015;135:2964–2970.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ma Y, Zhang Z, et al. Identification of two loci associated with generalized pustular psoriasis. J Invest Dermatol. 2015;135:2132–2134.
   PubMed Web of Science ®Google Scholar
• Farooq M, Nakai H, Fujimoto A, et al. Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis. Hum Mutat. 2013;34:176–183.
   PubMed Web of Science ®Google Scholar
• Takeichi T, Kobayashi A, Ogawa E, et al. Autosomal dominant familial generalized pustular psoriasis caused by a CARD14 mutation. Br J Dermatol. 2017;177:e133–e5.
   PubMed Web of Science ®Google Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620–628.
   PubMed Web of Science ®Google Scholar
• Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98:5–13.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133:2514–2521.
   PubMed Web of Science ®Google Scholar
• Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1792–1799.
   PubMed Web of Science ®Google Scholar
• Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27:1067–1077.
   PubMed Web of Science ®Google Scholar
• Expert Committee of Psoriasis SoD, Chinese Medical Association. Guidelines of diagnosis and treatment for psoriasis in China (2018 complete edition). Zhonghuo Pifuke Zazhi. 2018;10:667–710.
   Google Scholar
• Reichert-Penetrat S, Barbaud A, Antunes A, et al. An unusual form of Stevens-Johnson syndrome with subcorneal pustules associated with mycoplasma pneumoniae infection. Pediatr Dermatol. 2000;17:202–204.
   PubMed Web of Science ®Google Scholar
• Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.
   PubMed Web of Science ®Google Scholar
• Ly K, Beck KM, Smith MP, et al. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37–42.
   PubMed Web of Science ®Google Scholar
• Naik HB, Cowen EW. Autoinflammatory pustular neutrophilic diseases. Dermatol Clin. 2013;31:405–425.
   PubMed Web of Science ®Google Scholar
• Varman KM, Namias N, Schulman CI, et al. Acute generalized pustular psoriasis, von Zumbusch type, treated in the burn unit. A review of clinical features and new therapeutics. Burns. 2014;40:e35–9.
   PubMedGoogle Scholar
• Romiti R, Hirayama A, Arnone M, et al. Generalized pustular psoriasis (von Zumbusch). An Bras Dermatol. 2022;97:63–74.
   PubMed Web of Science ®Google Scholar
• Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45:1235–1270.
   PubMed Web of Science ®Google Scholar
• Neuhauser R, Eyerich K, Boehner A. Generalized pustular psoriasis-Dawn of a new era in targeted immunotherapy. Exp Dermatol. 2020;29:1088–1096.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741–751.
   PubMed Web of Science ®Google Scholar
• Morita A, Kotowsky N, Gao R, et al. Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: results from the medical data vision claims database. J Dermatol. 2021;48:1463–1473.
   PubMed Web of Science ®Google Scholar
• Reisner DV, Johnsson FD, Kotowsky N, et al. Impact of generalized pustular psoriasis from the perspective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23:65–71.
   PubMed Web of Science ®Google Scholar
• Okubo Y, Kotowsky N, Gao R, et al. Clinical characteristics and health-care resource utilization in patients with generalized pustular psoriasis using real-world evidence from the Japanese medical data center database. J Dermatol. 2021;48:1675–1687.
   PubMed Web of Science ®Google Scholar
• Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2012;67:279–288.
   PubMed Web of Science ®Google Scholar
• Kromer C, Loewe E, Schaarschmidt ML, et al. Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther. 2021;34:e14814.
   PubMed Web of Science ®Google Scholar
• Secukinumab (Genetical recombination) approval review report. Pharmaceuticals and Medical Devices Agency; 2015 [cited 2021 Sept 22]. Available from: https://www.pmda.go.jp/files/000216877.pdf
   Google Scholar
• Risankizumab (Genetical recombination) approval review report. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare; 2019 [cited 2021 Sept 22]. Available from: https://www.pmda.go.jp/files/000239461.pdf
   Google Scholar
• Guselkumab (Genetical recombination) approval review report. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare; 2018 [cited 2021 Sept 22]. Available from: https://www.pmda.go.jp/files/000234741.pdf
   Google Scholar
• Kirin KH. Lumicef® (Brodalumab) prescribing information. Thailand: Kyowa Hakko Kirin (Thailand) Co., Ltd. Bangkok. 2018.
   Google Scholar
• Zhu H, Song P, Du D, et al. Successful treatment of a 3-year-old girl with generalized pustular psoriasis using secukinumab monotherapy. Pediatr Dermatol. 2021;38:1366–1367.
   PubMed Web of Science ®Google Scholar
• Hansel K, Marietti R, Tramontana M, et al. Childhood generalized pustular psoriasis: successful long-term treatment with Adalimumab. Dermatol Ther. 2020;33:e13294.
   PubMed Web of Science ®Google Scholar
• Kołt-Kamińska M, Żychowska M, Reich A. Infliximab in combination with low-dose acitretin in generalized pustular psoriasis: a report of two cases and review of the literature. Biologics. 2021;15:317–327.
   PubMed Web of Science ®Google Scholar
• Strober B, Kotowsky N, Medeiros R, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of corrona registry dermatologists. Dermatol Ther (Heidelb). 2021;11:529–541.
   PubMed Web of Science ®Google Scholar
• Zhou LL, Georgakopoulos JR, Ighani A, et al. Systemic monotherapy treatments for generalized pustular psoriasis: a systematic review. J Cutan Med Surg. 2018;22:591–601.
   PubMed Web of Science ®Google Scholar
• Kearns DG, Chat VS, Zang PD, et al. Review of treatments for generalized pustular psoriasis. J Dermatolog Treat. 2021;32:492–494.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011–1017.
   PubMed Web of Science ®Google Scholar
• Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45:1371–1380.
   PubMed Web of Science ®Google Scholar
• Ji S. Meta-analysis of treatment with cyclosporine, methotrexate and acitretin for patients with generalized pustular psoriasis. Taishanyixueyuan Xuebao. 2018;39:973–978.
   Google Scholar
• Chinese Society of Dermatology CDA, Dermatology and Venereology Specialized Committee of Chinese Association of Integrative Medicine, Chen A-J, Gao X-H, Gu H, et al. Chinese experts consensus on biologic therapy for psoriasis#. IntJ Demat Venerol. 2020;3:76–85.
   Google Scholar
• Guselkumab injection prescription information. [cited 2021 Sept 22]. Avaibale from: https://www.xian-janssen.com.cn/sites/default/files/PDF/te_nuo_ya_yu_chong_bi_ni_yin_zhi_ban_shuo_ming_shu__2.pdf.Janssen-CilagInternationalNV2020
   Google Scholar
• Wu Y, Chen J, Shi X, et al. A case study of one patient with acute generalized pustular psoriasis treated with adalimumab. Zhongguo Pifu-Xingbingxue Zazhi. 2018;9:1032–1035.
   Google Scholar
• He M, Zhang JA, Xin W, et al. Efficacy evaluation of 7 patients with psoriasis treated with secukinumab. Zhongguo Mafeng Pifubing Zazhi. 2020;9:537–540
   Google Scholar
• Pan J, Qiu L, Xiao T, et al. Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab. Dermatol Ther. 2016;29:164–167.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao Y. Research progress on clinical therapies for generalized pustular psoriasis. Zhongguo Zhongyi Jizhen. 2020;7:1313–1316
   Google Scholar
• Wang Y, Yang H, Chen L, et al. Network-based modeling of herb combinations in traditional Chinese medicine. Brief Bioinform. 2021;22. DOI:10.1093/bib/bbab106.
   Web of Science ®Google Scholar
• Fan P. The current situation of Treatment For Generalized Pustular Psoriasis. Zhongguo Liaoyang Yixue. 2010;6:524–525.
   Google Scholar
• Zhou J. Research progress on biological agents for generalized pustular psoriasis. Pifukexue Tongbao. 2020;37:472–476
   Google Scholar
• Ricotti C, Kerdel FA. Subacute annular generalized pustular psoriasis treated with etanercept and cyclosporine combination. J Drugs Dermatol. 2007;6:738–740.
   PubMedGoogle Scholar
• Lo Schiavo A, Brancaccio G, Puca RV, et al. Etanercept in the treatment of generalized annular pustular psoriasis. Ann Dermatol. 2012;24:233–234.
   PubMed Web of Science ®Google Scholar
• Yuling S, Jun G, Zhizhong Z. The expert writing committee for the Chinese expert consensus on diagnosis and treatment in patients with pustular psoriasis. Chinese expert consensus on diagnosis and treatment in patients with pustular psoriasis (2022). Chin Jl of Dermatology. 2022;55:187–195.
   Google Scholar
• Jin H, Cho HH, Kim WJ, et al. Clinical features and course of generalized pustular psoriasis in Korea. J Dermatol. 2015;42:674–678.
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380:981–983.
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Effisayil™ 1: a multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of spesolimab in patients with a generalized pustular psoriasis flare. N Engl J Med. 2021;385:2431–2440.
   PubMed Web of Science ®Google Scholar
• Shahidi Dadras M, Diab R, Ahadi M, et al. Generalized pustular psoriasis following COVID-19. Dermatol Ther. 2021;34:e14595.
   PubMed Web of Science ®Google Scholar
• Pala E, Melikoğlu M, Erkayman MH. Pediatric COVID-19 patient with exacerbated generalized pustular psoriasis. Rev Soc Bras Med Trop. 2021;54:e0318.
   PubMed Web of Science ®Google Scholar
• Elamin S, Hinds F, Tolland J. De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine. Clin Exp Dermatol. 2022;47:153–155.
   PubMed Web of Science ®Google Scholar
• Onsun N, Kaya G, Işık BG, et al. A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report. Health Promot Perspect. 2021;11:261–262.
   PubMed Web of Science ®Google Scholar
• Perna D, Jones J, Schadt CR. Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. JAAD Case Rep. 2021;17:1–3.
   PubMedGoogle Scholar
• Talamonti M, Galluzzo M, Chiricozzi A, et al. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. J Eur Acad Dermatol Venereol. 2020;34:e770–e2.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Chiricozzi A, et al. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: risk analysis from the PSO-BIO-COVID observational study. Expert Opin Biol Ther. 2021;21:271–277.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Tofani L, Bianchi L, et al. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era. Expert Opin Biol Ther. 2020;20:829–830.
   PubMed Web of Science ®Google Scholar